ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1036

A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care

Rosemary Gedert1, Danielle Ochocki1, Neda Kortam1, Suiyuan Huang1, Vivek Nagaraja2, Katherine Chakrabarti1, Julia Ford1, Martin Garber1, Jiha Lee1, Vladimir Ognenovski1, David Roofeh3, David Cella4 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Rutgers-RWJ Medical School, New Brunswick, NJ, 4Northwestern University, Chicago, IL

Meeting: ACR Convergence 2024

Keywords: fibromyalgia, Osteoarthritis, Outcome measures, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient. This pilot aimed to assess the feasibility and impact of incorporating PROMIS® questionnaires at the point of care in rheumatology practice.

Methods: Patients with rheumatic diseases and decrements in ≥1 PROMIS® domain (pain intensity, physical function, or sleep disturbance) were stratified by their concerning domain, then randomized to either receive an interpretation of their PROMIS® scores before their rheumatology appointment (Arm 1) or to usual care (Arm 2) (ClinicalTrials.gov ID: NCT05026853). The primary outcome was the documentation of PROMIS® scores in the electronic medical record (EMR). Secondary outcomes include recommendations made by physicians based on PROMIS® scores, patient-provider communication, and change in the most concerning PROMIS® domain score from baseline to 12 weeks.

Results: 110 patients were enrolled. 55 were randomized to receive report cards (Arm 1), of which 46 received the report card, and 55 received usual care (Arm 2). Subjects had various rheumatologic conditions as described in Table 1. Documentation of PROMIS® scores in the EMR was present for 50% of subjects in Arm 1 (12.7% in Arm 2, p< 0.0001, Table 2). More recommendations were made based on PROMIS® scores for Arm 1 patients. There was no significant difference in post-visit PROMIS® score improvement between Arm 1 and Arm 2.

Conclusion: Providing PROMIS® report cards to patients and healthcare providers increased score documentation in the EMR. Increased recommendations made based on PROMIS® scores in Arm 1 suggest that having a score interpretation might help direct medical decision-making. PRO implementation could have various effects such as influencing patient health behaviors, detecting unrecognized problems, supporting discussions of PROs between patients and HCPs, and aiding HCPs in monitoring patients’ health.1 These factors contribute to the intermediate processes that occur before we can see improvement in the distal outcome of patient health status or quality of life. Our results demonstrate an improvement in the documentation of PRO scores in the EMR is a positive proximal outcome. This is a positive and necessary step to reach the distal outcome of improving patients’ outcomes.

References: 
1. Khanna, Dinesh et al. “The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS).” Arthritis care & research vol. 63 Suppl 11,Suppl 11 (2011): S486-90. doi:10.1002/acr.20581

Supporting image 1

Table 1: Baseline Characteristics of Subjects. Arm 1 patients received PROMIS® report cards prior to their rheumatology appointment. Arm 2 received usual care.
Some patients advocated >1 diagnosis.
+ indicates higher score is better, – indicates lower score is better.

Supporting image 2

Table 2: Primary and Secondary Outcome Measures. Arm 1 patients received PROMIS® report cards prior to their rheumatology appointment. Arm 2 received usual care.


Disclosures: R. Gedert: None; D. Ochocki: None; N. Kortam: AstraZeneca, 7; S. Huang: None; V. Nagaraja: None; K. Chakrabarti: None; J. Ford: None; M. Garber: None; J. Lee: None; V. Ognenovski: None; D. Roofeh: None; D. Cella: None; D. Khanna: AbbVie/Abbott, 2, Amgen, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Certa Therapeutics, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, MDI Therapeutics, 8, Merck/MSD, 2, Novartis, 2, Zura Bio, 2.

To cite this abstract in AMA style:

Gedert R, Ochocki D, Kortam N, Huang S, Nagaraja V, Chakrabarti K, Ford J, Garber M, Lee J, Ognenovski V, Roofeh D, Cella D, Khanna D. A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-pilot-trial-of-integrating-patient-reported-outcome-measurement-information-system-promis-into-rheumatology-care/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pilot-trial-of-integrating-patient-reported-outcome-measurement-information-system-promis-into-rheumatology-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology